ClinicalTrials.gov
ClinicalTrials.gov Menu

CLCNKA (Ka Renal Chloride Channel[ClC-Ka]) Polymorphism Effects on Hypertrophy Regression

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01275352
Recruitment Status : Withdrawn (Lack of funding)
First Posted : January 12, 2011
Last Update Posted : June 3, 2015
Sponsor:
Collaborator:
University of Pennsylvania
Information provided by:
Washington University School of Medicine

Study Description
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This study will consist of middle-aged Caucasian non-failing subjects with high blood pressure who are homozygous for a gene that confers increased risk of developing heart failure, the Glycine 83 variant of the Ka renal chloride channel (ClC-Ka Gly/Gly 83), or middle-aged Caucasian non-failing hypertensive subjects who lack the heart failure risk gene, the wild-type Arginine 83 Ka renal chloride channel (ClC-Ka Arg/Arg 83). Subjects on standard therapy for high blood pressure with an angiotensin converting inhibitor (ACEI) or angiotensin receptor blocker (ARB) will be randomized to additional treatment with eplerenone (an aldosterone antagonist) or placebo, and assessed for changes in echocardiographic left ventricular hypertrophy (LVMI). Secondary endpoints will assess left ventricular remodeling and other echocardiographic variables. The investigators hypothesize that subjects homozygous for the CLCNKA risk allele will have a greater response to eplerenone in terms of reductions in LVMI than those lacking the risk allele.

Condition or disease Intervention/treatment Phase
Hypertension Drug: Eplerenone Drug: placebo Phase 4

Detailed Description:
The screening phase will involve identifying Caucasian hypertensive patients who are homozygous for the ClC-Ka Gly/Gly83 and the ClC-Ka Arg/Arg 83 allele. All patients will be on background therapy with an angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) at least mid range dosing. If patient is not at recommended dose of ACE or ARB they must be titrated up and be stable on a midrange dose of ACEI or ARB for at least 4 weeks before they can be entered into the study. There will be 2 treatment phases. Phase 1 will be up to 4 weeks in duration and will consist of randomization to one table of eplerenone (25 mg) or matching placebo. On week 2 the patient will be up titrated to two tablets of eplerenone (50 mg) or matching placebo, to achieve a target dose of 50 mg of eplerenone. If the patient cannot tolerate two tablets of eplerenone or matching placebo they can be down titrated to one tablet of eplerenone or matching placebo. The target BP on study medication is < 130/80 mmHg. After the patients have been up titrated to the maximally tolerated dose of study medication, the background hypertension therapy can be adjusted to reach the target BP of < 130/80 mmHg by the end of week 4. Phase 2 will be 52 weeks in duration to assess the effects of placebo or eplerenone on LV hypertrophy. Serum potassium will be monitored throughout the study, and if necessary, doses of eplerenone will be titrated down as necessary.

Study Design
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double Blind Pilot Study Evaluating CLCNKA (Ka Renal Chloride Channel[ClC-Ka]) Polymorphism Effects on Hypertrophy Regression in Caucasian Hypertensive Patients Treated With Eplerenone
Study Start Date : December 2011
Estimated Primary Completion Date : December 2014
Actual Study Completion Date : June 2015

Resource links provided by the National Library of Medicine

Drug Information available for: Eplerenone
U.S. FDA Resources

Arms and Interventions
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: Arm 1
Caucasian hypertensive patients who are homozygous for the ClC-Ka Gly/Gly83 allele
 Drug: Eplerenone
Eplerenone 50 mg/day
Other Names:
  • Inspra
  • aldosterone antagonist
Active Comparator: Arm 2
Caucasian hypertensive patients who are homozygous for ClC-Ka Arg/Arg 83 allele
 Drug: Eplerenone
Eplerenone 50 mg/day
Other Names:
  • Inspra
  • aldosterone antagonist
Placebo Comparator: Arm 3
Caucasian hypertensive patients who are homozygous for ClC-Ka Arg/Arg 83 allele
 Drug: placebo
placebo
Placebo Comparator: Arm 4
Caucasian hypertensive patients who are homozygous for the ClC-Ka Gly/Gly83 allele
 Drug: placebo
placebo


Outcome Measures
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Change in LV mass index (g/m2) in ClC-Ka Gly/Gly83 patients and ClC-Ka Gly/Gly83 patients [ Time Frame: 12 months ]

Secondary Outcome Measures :
  1. Change in LV relative wall thickness [ Time Frame: 6 and 12 months ]
  2. Change in N-terminal pro-brain natriuretic peptide (NT-proBNP) [ Time Frame: 6 and 12 months ]
  3. Change in LV mass index (g/m2) [ Time Frame: 6 months ]

Eligibility Criteria
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Caucasians with hypertension who are homozygous for the ClC-Ka Gly/Gly83 and the ClC-Ka Arg/Arg 83 allele.
  2. Male or non-pregnant female aged 40 to 80 years.
  3. Hypertension, defined as currently taking high blood pressure medications or not on medications but having SDP >140 or DBP >90.
  4. Ejection fraction > 50% by any method within 6 months of the screening visit.
  5. The Investigator must obtain written informed consent before the subject is screened for the study.
  6. Subject should be on stable dose of ACE or ARB at moderate dosing for at least 4 weeks before randomization.

Exclusion Criteria:

  1. History of heart failure with preserved or depressed ejection fraction.
  2. Creatinine clearance of < 45 mL/min based on the Cockcroft-Gault formula (Appendix C).
  3. Pregnancy
  4. Life expectancy less than 12 months.
  5. Planned cardiac surgery or percutaneous cardiac intervention within 3 months.
  6. Serum potassium >5.5 mEq/L.
  7. History of hyperkalemia (K>6.0 mEq/L) with eplerenone or spironolactone.
  8. Myocardial infarction or stroke within 3 months of screening.
  9. Evidence of clinical instability (hypotension, arrhythmias, unstable angina etc.).
  10. Subjects on or requiring K-sparing diuretics or spironolactone.
  11. Concomitant use of potent inhibitors of CYP3A4 including ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, and nelfinavir or any drug noted in the Contraindications, Warnings or Precautions sections of their labeling to be potent CYP3A4 inhibitors
  12. Known hypersensitivity to eplerenone or spironolactone.
  13. Evidence of current alcohol or drug abuse Severe organic disorders or surgery or disease of the gastrointestinal tract that in the opinion of the Investigator may interfere in the absorption and elimination of the study drug.
  14. Psychoses or behavioral conditions that in the opinion of the Investigator would limit study compliance.
  15. Subjects who have received any investigational medication or used any investigational device within 30 days prior to first dose of study drug or subjects actively participating in any investigational drug or device study.
Contacts and Locations
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01275352


Locations
United States, Missouri
Barnes Jewish Hospital
St. Louis, Missouri, United States, 63108
United States, Pennsylvania
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Sponsors and Collaborators
Washington University School of Medicine
University of Pennsylvania
Investigators
Principal Investigator: Thomas Cappola, MD University of Pennsylvania
Principal Investigator: Gerald Dorn, MD Washington University School of Medicine
More Information
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party: Thomas Cappola, MD, ScM, University of Pennsylvania
ClinicalTrials.gov Identifier: NCT01275352     History of Changes
Other Study ID Numbers: CLNCKA-1
First Posted: January 12, 2011    Key Record Dates
Last Update Posted: June 3, 2015
Last Verified: June 2015

Keywords provided by Washington University School of Medicine:
left ventricular hypertrophy
heart failure

Additional relevant MeSH terms:
Hypertrophy
Pathological Conditions, Anatomical
Eplerenone
Spironolactone
Mineralocorticoid Receptor Antagonists
Hormone Antagonists
 Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Diuretics, Potassium Sparing
Diuretics
Natriuretic Agents